Borapetoside E has anti-hyperglycemic activity, it can significantly reduce serum glucose levels at dose-dependent manners in alloxan-induced hyperglycemic mice and db db type 2 diabetic mice.
5-O-Coumaroylquinic acid (3-O-Coumaroylquinic acid), exhibits significant inhibition of PTP1B and a concentration-dependent inhibitory effect on α-glucosidase, thereby demonstrating anti-hyperglycemic properties. Additionally, this compound enhances glucose uptake and inhibits PTP1B in vitro, emphasizing its potential therapeutic applications in glucose regulation.